While still in clinical trials, these tests are seen to be much closer to clinical use than previously thought, and are expected to complement, rather than replace, current cancer detection options. This was the outlook a year ago. So, where do we stand today? How close are we to having these tests available?
The Galleri test, through a simple blood draw, has the capability to detect a signal shared by more than 50 cancer types and predict the tissue type or organ associated with the signal to help healthcare providers determine next steps.
By using multi-cancer early detection, GRAIL’s Galleri® test can improve the health and longevity of policyholders with an elevated cancer risk
RGA's Dr. Radi Counsell reviews how modern immunotherapy is transforming cancer outcomes, and the real possibility that it might even cure some highly lethal cancers such as malignant melanoma
The number of people living after a cancer diagnosis (i. e. prevalent cases) has been increasing for the past 30 years, reaching around 5 % of the total population in several countries.
What if people could be screened for more types of cancer with a single test?
In this edition of ReCent Medical News, Monique Esterhuizen reflects on how genomics enable us to “look under the hood” of a tumor and develop the most suitable personalized treatment. Furthermore she explores what insurers need to know about these promising cancer treatments.
In this second interview of a 4-part series, Dr. Achim Regenauer answers questions relevant to Life & Health underwriters on advances in cancer diagnostics.
Dr. Achim Regenauer discusses how far we are along the road to having multi-cancer early detection tests – essentially powerful liquid biopsies – in the clinical setting. It appears that this is much closer than previously assumed, and that these tests will complement, rather than replace, current detection options.
In this, the last of our 4-part series of insurance-focused articles on cancer, Dr. Achim Regenauer, Chief Medical Officer, presents a high-level overview of how genomic sequencing of cancers is blasting a trail for improved, early diagnosis and precision medicine by providing a powerful and ever-expanding means to detect, identify, subdivide and monitor cancer – and how this remarkable development could impact Life & Health insurers.